Androgenetic Alopecia: The Four-Axis Protocol Validated by Science

Male androgenetic alopecia is not a cosmetic fatality, but a biological process whose molecular mechanisms have been documented for over three decades. In a community-based sample of men aged 18 to 49, 42% had moderate to extensive hair loss, a proportion rising from 16% between 18 and 29 to 53% between 40 and 49 (PubMed ). What makes it particular is that the scientific literature offers a structured, reproducible, dose-dependent protocol. Four axes of intervention now have a sufficient level of evidence to be presented as a coherent foundation.

DHT and the miniaturization cascade

Circulating testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, present in high concentration in scalp follicles. DHT binds to androgenic receptors in the hair follicle and triggers a progressive shortening of the anagen phase, the part of the hair cycle during which the hair actively grows. Each cycle produces a thinner, shorter, less pigmented hair. This is follicular miniaturization.

This process is not uniform. It follows a genetically determined pattern, mapped by the Norwood-Hamilton scale. The temporal zones and vertex are most sensitive to DHT. The occipital zone (back of the skull) is largely spared, which explains its use as a donor area in hair transplant surgery.

The critical point is this: once a follicle is completely miniaturized, regeneration becomes improbable. Early intervention is therefore a biological constraint, not a matter of comfort.

The four axes validated by the literature

Oral finasteride: enzymatic inhibition

Finasteride is a selective inhibitor of type II 5-alpha reductase. At a dosage of 1 mg/day, it reduces serum DHT by approximately 70% (PubMed ). Phase III clinical trials demonstrated an increase in hair count and improvement in clinical appearance in 83% of participants after two years.

Without DHT inhibition, other interventions merely slow a process whose cause remains active. This is why finasteride constitutes the first axis of any structured protocol.

Sexual side effects (decreased libido, erectile dysfunction) affect 2 to 4% of users and are reversible upon discontinuation in the vast majority of cases. Medical supervision remains essential.

Topical minoxidil: vascular stimulation

Minoxidil (5% solution) acts through a distinct mechanism. It prolongs the active growth phase of the hair and accelerates the return of resting follicles into a new growth cycle (PubMed ). Its action involves the opening of ion channels in vascular cells, which causes blood vessel dilation in the scalp and improves nutrient delivery to the follicles.

Application is twice daily. Initial results generally appear between 4 and 6 months. A shedding phenomenon (temporary accelerated hair loss) frequently occurs in the first few weeks. This is a positive signal: resting follicles are being forced into a new growth cycle.

Ketoconazole: the antifungal and local anti-androgenic axis

Ketoconazole shampoo (2% concentration) has shown effects on hair density and size comparable to those of 2% minoxidil in a clinical trial (PubMed ). Its mechanism of action extends beyond the antifungal effect: it reduces local testosterone production on the scalp and decreases inflammation around the follicles.

Recommended use is 2 to 3 times per week, leaving the product in contact with the scalp for 3 to 5 minutes before rinsing. This is the least demanding axis of the protocol and the one with the most favorable safety profile.

Microneedling: mechanical activation of growth factors

Scalp microneedling (dermaroller or dermapen, 0.5 to 1.5 mm needles) triggers a controlled wound-healing response. This response activates the Wnt/beta-catenin pathway, a signaling cascade that instructs stem cells to regenerate the follicle. It also stimulates the release of growth factors (PDGF, VEGF) that promote vascularization and cell proliferation.

A randomized clinical trial demonstrated statistically significant superiority of the microneedling + minoxidil group compared to minoxidil alone (PubMed ). The combined group showed a mean hair count increase of 91.4 versus 22.2 for minoxidil alone after 12 weeks.

Recommended frequency is one session per week. Sterilizing the device with alcohol before and after each use is mandatory.

Emerging axes: what is taking shape

Three molecules are progressively expanding the available arsenal, without replacing the four preceding axes.

Dutasteride inhibits both isoforms of 5-alpha reductase (I and II), blocking more than 90% of DHT (PubMed ). Its half-life (the time required for the body to eliminate half the molecule) is 5 weeks, compared to 8 hours for finasteride. Side effects therefore persist longer after discontinuation. It remains prescribed outside its official indication for alopecia in most European countries and is intended for finasteride non-responders.

Low-dose oral minoxidil (0.625 to 2.5 mg/day) represents an alternative for patients in whom the topical form fails. The enzymatic conversion of minoxidil to its active form (minoxidil sulfate) occurs primarily in the liver, which explains why the oral route can prove more effective than the topical route in certain individuals. Blood pressure monitoring is imperative.

PP405 constitutes the most novel approach. It blocks a transporter located in mitochondria (the cell's energy powerhouses), which alters the metabolism of follicle stem cells and promotes their activation. Its Phase 2a trial enrolled 78 men and women, treated for 28 days (study ). The sponsor reports that at week eight, four weeks after the end of treatment, 31% of men with more advanced hair loss had gained more than 20% in hair density, against 0% on placebo (press release ). That figure comes from an exploratory analysis, the trial having registered no efficacy endpoint, and no Phase 3 was registered as of August 30, 2026. The full file is covered in a dedicated article.

What biology imposes as a conclusion

Androgenetic alopecia is not a domain where empiricism works. Supplements based on biotin, saw palmetto, or marine collagen, despite their popularity, do not have a level of evidence comparable to the four axes described above. Biotin has documented interest only in rare cases of confirmed deficiency, not in standard androgenetic alopecia.

The protocol that emerges from the literature follows a transparent logic: block the cause (DHT), stimulate growth (minoxidil), reduce local inflammation (ketoconazole), activate mechanical regeneration (microneedling). Four distinct, complementary, dosed, and documented mechanisms.

Ongoing research on PP405 and oral minoxidil forms suggests that this arsenal will continue to expand. But the foundation has remained the same for two decades. It is solid. And it is available.

Frequently asked questions

Why is finasteride considered the first axis of the protocol?#[ + ]

Finasteride blocks approximately 70% of the conversion of testosterone to DHT, the molecule directly responsible for follicular miniaturization. Without this enzymatic inhibition, other interventions (minoxidil, microneedling) only slow a process whose root cause remains active. This is why it forms the foundation of any structured protocol.

What is shedding and should it cause concern?#[ + ]

Shedding is a temporary acceleration of hair loss that occurs in the first weeks of minoxidil treatment. It is a positive signal: resting follicles are being forced into a new growth cycle. This phenomenon is transient and generally precedes improved regrowth.

Why not start finasteride and minoxidil at the same time?#[ + ]

If both molecules are introduced simultaneously, it is impossible to attribute results to either one. The recommendation is to start with finasteride, evaluate the response over 12 months, then add minoxidil if needed. This sequencing allows rational protocol adjustment.

Are biotin or saw palmetto supplements effective against androgenetic alopecia?#[ + ]

No, these supplements do not have a level of evidence comparable to the four validated axes (finasteride, minoxidil, ketoconazole, microneedling). Biotin has documented benefit only in rare cases of confirmed deficiency, not in standard androgenetic alopecia.

How long before visible results can be expected?#[ + ]

Regardless of the combination chosen, visible results require 6 to 24 months. Photographic tracking under identical lighting conditions enables objective assessment. Shedding phases are normal and often indicate a positive treatment response.

---

References

1. Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg. 1998;24(12):1330-1332 (PubMed ).
2. Kaufman KD, Dawber RP. Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia. Expert Opin Investig Drugs. 1999;8(4):403-415 (PubMed ).
3. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385 (PubMed ).
4. Hugo Perez BS. Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62(1):112-115 (PubMed ).
5. Dhurat R, Sukesh M, Avhad G, et al. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia. Int J Trichology. 2013;5(1):6-11 (PubMed ).
6. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023 (PubMed ).
7. Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA. ClinicalTrials.gov. NCT06393452 (study ).
8. Pelage Pharmaceuticals. Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy. Press release, June 17, 2025 (press release ).